tirzepatide in heart failure the SUMMIT trial, researchers examined cardiovascular outcomes of treatment with in patients with with preserved ejection fraction and obesity. Full trial results and Plain Language Summary: https://t.co/8joe2mst3e 💊 New research in obesity

Most treatment protocols begin at lower dosestypically 2.5 mg or 5 mgand escalate gradually every four weeks to minimize gastrointestinal side effects and allow your body to adapt

Potential complementary evidence of GLP-1RAs and SGLT2is In a meta-analysis comparing the effects of GLP-1RAs with SGLT2is, five GLP-1RA (ELIXA, LEADER, SUSTAIN-6, EXSCEL, and Harmony Outcomes) and three SGLT2i trials (EMPA-REG OUTCOME, CANVAS Program, and DECLARE-TIMI 58) with a total of 77,242 patients were include [35]

Moisturizing Agents: Keep skin soft and prevent dryness

Users have also reported ongoing pain in the upper middle or left stomach areas